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STUDY PROTOCOL Open Access
A stepped-wedge randomised-controlled
trial assessing the implementation, impact
and costs of a prospective feedback loop
to promote appropriate care and treatment
for older patients in acute hospitals at the
end of life: study protocol
Xing J. Lee1,2* , Alison Farrington1,2, Hannah Carter1,2, Carla Shield1,2, Nicholas Graves3, Steven M. McPhail1,2,
Gillian Harvey1,2,4, Ben P. White5, Lindy Willmott5, Magnolia Cardona6,7, Ken Hillman8, Leonie Callaway9,10,11 and
Adrian G. Barnett1,2
Abstract
Background: Hospitalisation rates for the older population have been increasing with end-of-life care becoming a
more medicalised and costly experience. There is evidence that some of these patients received non-beneficial
treatment during their final hospitalisation with a third of the non-beneficial treatment duration spent in intensive
care units. This study aims to increase appropriate care and treatment decisions and pathways for older patients at
the end of life in Australia. This study will implement and evaluate a prospective feedback loop and tailored clinical
response intervention at three hospitals in Queensland, Australia.
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Methods: A stepped-wedge cluster randomised trial will be conducted with up to 21 clinical teams in three acute
hospitals over 70 weeks. The study involves clinical teams providing care to patients aged 75 years or older, who are
prospectively identified to be at risk of non-beneficial treatment using two validated tools for detecting death and
deterioration risks. The intervention’s feedback loop will provide the teams with a summary of these patients’ risk
profiles as a stimulus for a tailored clinical response in the intervention phase. The Consolidated Framework for
Implementation Research will be used to inform the intervention’s implementation and process evaluation. The
study will determine the impact of the intervention on patient outcomes related to appropriate care and treatment
at the end of life in hospitals, as well as the associated healthcare resource use and costs. The primary outcome is
the proportion of patients who are admitted to intensive care units. A process evaluation will be carried out to
assess the implementation, mechanisms of impact, and contextual barriers and enablers of the intervention.
Discussion: This intervention is expected to have a positive impact on the care of older patients near the end of
life, specifically to improve clinical decision-making about treatment pathways and what constitutes appropriate
care for these patients. These will reduce the incidence of non-beneficial treatment, and improve the efficiency of
hospital resources and quality of care. The process evaluation results will be useful to inform subsequent
intervention implementation at other hospitals.
Trial registration: Australia New Zealand Clinical Trial Registry (ANZCTR), ACTRN12619000675123p (approved 6 May
2019),
Keywords: End-of-life care, Geriatrics, High-risk, older population, Risk assessment, Intensive care, Medical futility,
Non-beneficial treatment, Prospective feedback loop intervention, Stepped-wedge cluster randomised trial
Background
The older population is increasing worldwide as a result
of longer life expectancy and lowered fertility rates [1].
Older persons typically have increased frailty, chronic
health conditions and multiple morbidities [2, 3]. While
health care use and expenditure in this population is
variable, health care expenditure is markedly higher at
the end of life [2, 4].
There are challenges to caring for this older popula-
tion in acute care settings. Specifically, clinicians, pa-
tients and families grapple with tensions between the
limits of medicine, subjective judgements about benefi-
cence, and economic and clinical imperatives to provide
appropriate and quality patient care [5]. Clinicians pro-
viding end-of-life care, who are often tasked with pre-
paring patients and families for a transition to palliative
and supportive care pathway [6], frequently experience
barriers to these discussions [7, 8]. This leads to an in-
crease in non-beneficial treatment, causes moral distress
to clinicians, and prolongs or increases patient suffering
[9]. A systematic review of 38 international studies
found 33 to 38% of patients received non-beneficial
treatment at the end of life [10].
These barriers have been broadly categorised as arising
from clinician factors, hospital factors and patient factors
[7, 11–14]. Addressing these factors is challenging, espe-
cially in large, complex acute care settings. Evidence ex-
ists for interventions to reduce non-beneficial treatment
outside of acute hospitals [15–18], and an intervention
study has been done in the Intensive Care Unit (ICU)
setting in the United States [19]. There is no published
research in Australia evaluating an intervention to re-
duce non-beneficial treatment at the end of life in
hospitals.
As with other developed countries, Australia’s health
care system faces urgent challenges from an ageing
population. This population is more likely to be hospita-
lised than in the past, with hospitalisation rates for
people aged over 85 years increasing by 35% for women
and 48% for men in the decade to 2011 [20]. The end-
of-life phase in Australia is becoming an increasingly
medicalised experience with 54% of deaths occurring in
hospital [21]. A retrospective study [22] of three Austra-
lian hospitals in 2012 identified 12.1% (range 6.0 to
19.3%) of end-of-life admissions received non-beneficial
treatment. These admissions received non-beneficial
treatment for an average of 15 days including 5 days
spent in the ICU. This same study estimated an annual
national health system cost of $A153 million due to
non-beneficial bed days.
The Intervention for Appropriate Care and Treatment
(InterACT) study will implement a prospective, tailored
feedback loop intervention in three acute hospitals in
Queensland, Australia. We will evaluate whether the
intervention improves care outcomes for older patients,
specifically to increase appropriate care and treatment
pathways, and reduce the incidence of non-beneficial
treatments. This study will use two validated tools con-
currently to prospectively identify patients at the end of
life where curative and life-sustaining interventions may
be non-beneficial. The Criteria for Screening and Triag-
ing to Appropriate aLternative Care (CriSTAL) tool was
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developed to identify elderly patients in the last months
of life [23–25]. The Supportive and Palliative Care Indi-
cators Tool (SPICT™) can be used to identify patients at
risk of deteriorating and dying [26] with recent studies
reporting an association between a SPICT-positive result
and one-year mortality [27, 28].
Patient screening with both tools will be the first step
in the prospective feedback loop intervention. Providing
feedback to clinical teams aims to increase clinician
awareness of their patients’ risk profile, directly address-
ing some of the known clinician and hospital factors for
non-beneficial treatment [29–31]. A tailored clinical re-
sponse to this information will be determined and im-
plemented by the clinical teams, with support from a
hospital executive advisory group.
The primary objective of the study is to determine the
impact of a tailored clinical team feedback loop interven-
tion on outcomes related to appropriate care and treat-
ment at the end of life. The extent of change in health
service use and costs will also be estimated. A second ob-
jective is to conduct a process evaluation to assess imple-
mentation, mechanisms of impact, and contextual barriers
and enablers of the feedback loop intervention.
Methods/design
Study design
This is a randomised controlled trial using a multi-
centre stepped-wedge randomised design (Fig. 1). Five
stages will be sequentially rolled-out across the three
hospitals over 70 weeks: site preparation; usual care ex-
posure; intervention establishment; intervention expos-
ure; and post-intervention. The timing of the one-way
crossover from usual care to intervention establishment
will be randomly allocated.
Study setting and population
This trial will be undertaken at three large, acute
Queensland teaching hospitals. We will aim to enrol
seven clinical teams at each hospital. In consultation
with the local hospitals’ executive advisory group, we
will purposively sample from acute-care clinical teams
and medically-oriented clinical specialities that have a
regular number of patient admissions ≥75 years. This
supports trialling the intervention in clinical teams that
routinely have an older patient population who are more
likely to receive non-beneficial treatment.
For inclusion, clinical teams must:
 be an established clinical team unit or specialty that
routinely admits patients within the hospital
 include at least one nominated lead specialist consultant
 include at least one registrar and affiliated clinical
nurse consultant or nurse unit manager
 have a clinical team structure and admission pattern
typical of the hospital
 have a consistent history of admitting patients aged
75 years or over during the previous year
 participate in an information session with the
project team.
Excluded clinical teams will additionally include those
already implementing interventions or initiatives related
to reducing non-beneficial treatments for older patients,
and those from the emergency department, any Inten-
sive Care Units (ICUs), mental health units, and non-
acute care. The excluded specialities likely have different
clinical and treatment focus which would require a dif-
ferent implementation plan.
At each hospital, enrolled clinical teams, executive ad-
visory group members and site study team members will
be recruited for the process evaluation. Site study team
members will include hospital employees who have a
role in supporting the implementation of the trial or in
data collection, as determined in the site preparation
phase, and may include the nurse auditor, site coordin-
ator, and palliative care team.
Intervention
The study intervention (InterACT) is a prospective feed-
back loop to clinical teams with tailored clinical
Fig. 1 Stepped-wedge study design in three hospitals with seven teams per hospital for the InterACT trial
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response, based on the outcomes of a patient record re-
view (or screening) process using the CriSTAL and SPIC
T tools. The intervention process is shown in Fig. 2.
For the purpose of this study, patients are considered
to be in the at-risk population if they were identified to
be high-risk CriSTAL and SPICT-positive. Patients are
classified as high-risk CriSTAL (at high risk of death
within 3 months) if they have a CriSTAL score of 6 or
greater. Patients with a SPICT general indicator score of
2 or greater are considered SPICT-positive (presence of
indicators of potential deterioration within 12 months).
Site based trained auditors will review patient records
of new admissions to participating clinical team twice
weekly to identify patients in the at-risk population. Rec-
ord review data will be collected using an electronic
form in REDCap [32].
The feedback loop
In the intervention exposure phase, the study team will
provide feedback based on the record review results to
individual clinical team nominees after each screening
episode. The study team will develop computer scripts
to automate the processes of exporting the data from
REDCap into R [33], processing the data and generating
the feedback report. The project manager will provide
the feedback report to clinical team nominees in an
agreed format. The feedback report process includes
email, text or database log-in (or a combination of).
This feedback is intended to flag that a patient is in
the at-risk population, and to act as a stimulus to review
patient care activities and pathways [30, 34]. Clinician
expertise and autonomy will not be questioned in the
feedback, nor will judgements be made about the likeli-
hood of non-beneficial treatment. Examples of potential
clinician response to the feedback include palliative care
referral, multidisciplinary team review, advance care
planning consultation, and patient/family meetings.
Implementation framework
We will use the Consolidated Framework for Implemen-
tation Research (CFIR) [35] to inform the implementa-
tion and process evaluation of the InterACT study
intervention. The intervention will be fully described in
a CFIR-based implementation toolkit that identifies what
parts of the feedback loop intervention will be fixed,
what will be flexible, and the associated degree of
flexibility.
The toolkit will support the local tailoring of the inter-
vention to reflect hospital context, clinical team struc-
ture and workflows. The project team, study team,
hospital executive advisory group and enrolled clinical
teams will collaboratively develop and pilot an effective
feedback loop and associated clinical team response dur-
ing the intervention establishment phase.
Monitoring and evaluating implementation
Process evaluation is an essential part of designing and
testing complex interventions [36]. The real-world set-
ting and length of this trial will require a pragmatic ap-
proach to fostering intervention adherence, reach and
fidelity. The project team will systematically monitor the
implementation process as part of the process evaluation
using templates and approaches based on the CFIR con-
structs. This embedded approach will provide direct
support for implementing the InterACT study interven-
tion and will inform understanding of how the imple-
mentation process contributes to the study outcomes.
Study outcomes
The study outcomes and outcome measures are de-
scribed in Table 1. Outcomes 1 to 9 are for patients ad-
mitted under the enrolled clinical teams and identified
to be in the at-risk population following screening with
the CriSTAL tool and SPICT. The measurement tools
used are summarised online [37].
Fig. 2 Schematic of the InterACT intervention to be implemented
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We chose ICU admissions as the primary outcome as
the at-risk population is less likely to benefit from ICU
admission, and it is a commonly used proxy for non-
beneficial treatment in hospital [10]. That said, this is a
complex trial and the overall impact of the intervention
will be more appropriately represented through consid-
eration of all outcomes listed.
Study procedures
Recruitment, enrolment and withdrawal
The project manager will invite eligible clinical teams to
participate at routine meetings in the hospitals during
the recruitment period. The project manager, an execu-
tive sponsor and site-based study coordinator will ex-
plain the study and what is involved. All interested
clinicians will have access to the participant information
sheets and full study protocol [37].
Clinical teams will be enrolled by the project manager.
A nominated lead clinician will provide agreement on
behalf of their clinical team. As the unit of enrolment is
the clinical team, if an individual clinician participant,
including the lead clinician, withdraws from the study,
data collection and clinical team participation will con-
tinue unchanged.
Once enrolled, clinical team participation will only be
discontinued if ongoing participation is untenable or
negatively impacting patient care. The trial will only be
discontinued if a regulatory body, funding body, or eth-
ics committee judges it necessary for medical, safety,
regulatory, or other reasons consistent with applicable
laws, regulations and good clinical practice.
Randomisation, allocation and blinding
All three hospitals will receive the intervention, with the
timing randomised. A statistician investigator (XJL) will
be responsible for computer generation of the trial tim-
ing randomisation as per Fig. 1 and the intra-hospital
clinical team identifiers. These identifiers will help an-
onymise the data storage and reporting.
Table 1 Project outcomes and outcome measures for the InterACT study
Outcome label Outcome Outcome measure
Impact outcomes
Primary outcome
(Outcome 1)
Proportion of patients with one or more
Intensive Care Unit (ICU) admissions
ICU admissions during the current hospital stay from the date first
recorded as high-risk CriSTAL and SPICT-positive.
Outcome 2 Length of hospital stay and discharge
outcome
Length of hospital stay, with the transition endpoints of ‘discharged
alive’ and ‘death in hospital’, from the date first recorded as high-risk
CriSTAL and SPICT-positive.
Outcome 3 Time to hospital re-admission The time in days to re-admission to any Queensland public hospital
for re-admissions within 12 weeks from the date of discharge.
Outcome 4 Time to first documented indications
of clinician-led care review discussion
The time in days from the date first recorded as high-risk CriSTAL and
SPICT-positive to documentation of a clinician-led care review activity.
The type of care review activity (reduce/cease active treatment, increase
comfort care, continue active treatment) and indications of family conflict
will also be recorded.
Outcome 5 Time to first care directive measure The time in days from the date first recorded as high-risk CriSTAL and
SPICT-positive to documentation of any care directive (including discussion
outcomes, advance care plan, statement of choices, acute resuscitation
plan). The type of care directive will also be recorded.
Outcome 6 Time to first palliative care referral The time in days to first documented palliative care referral from the date
first recorded as high-risk CriSTAL and SPICT-positive during the current
hospital stay.
Outcome 7 Time to first medical emergency call The time in days to first medical emergency call during the current
hospital stay.
Health care resource use and cost outcomes
Outcome 8 Changes in admission/hospitalisation
and treatment costs
Costs of treatment will be taken from routinely collected information and
will begin accumulating from the date first recorded as high-risk CriSTAL
and SPICT positive. This ensures that treatment costs reflect only those costs
that relate to care provided at the end-of-life phase. All costs will be stratified
by the acute and palliative care phases so that any changes resulting from
different treatment pathways can be identified.
Outcome 9 Cost of implementing the prospective
feedback loop intervention
The cost of implementing the study intervention will be measured by the
duration and unit costs of staff time associated with completing direct trial
activities (including document review and clinical team feedback activities).
Process outcomes
Extent and fidelity of intervention implementation, impact, and contextual barriers and enablers of the feedback loop intervention
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Given the nature of the intervention and trial design,
it is not possible to blind the clinical teams to the inter-
vention. The intervention exposure phase commence-
ment date will be concealed from the hospital teams
during the site preparation and clinical team recruitment
phase. Hospital teams will be notified of their interven-
tion establishment and intervention exposure start dates
about 8 weeks prior to allow time to plan for the inter-
vention establishment phase activities.
Data collection
Site-based trained nurse auditors will prospectively col-
lect identifiable patient data during record screening
using an online form in REDCap. The auditors will re-
view patient records of all new admissions to participat-
ing clinical teams twice weekly to identify patients in the
at-risk population. At-risk patients will be passively
monitored at subsequent screening times if they have
not been discharged or transferred to a different facility.
Auditors will record if and when these patients had doc-
umented indications of clinician-led care review discus-
sion, care directive measures, and palliative care referral.
Data custodians will link outcome data for patients at
the end of the intervention exposure period.
Members of the clinical team and the site-based study
team will be asked to complete monitoring documents,
including capturing time spent on intervention activities,
to assess adherence to and fidelity of the intervention.
Process evaluation data will be collected using templates
based on the CFIR. Clinical team members will be invited
to participate in group or individual interviews after the
pilot in the intervention establishment phase, during the
intervention exposure phase, and during the post-
intervention phase. The hospital advisory group and site-
based study teams will also be asked to voluntarily partici-
pate in a group or individual interview about the imple-
mentation process during the post-intervention phase.
Additional details on the data items, collection
methods and schedule, and data management are pro-
vided online [37].
Data analyses
Sample size and statistical power
Simulation-based sample size calculations [38] were used
to determine an adequate sample size to detect the change
associated with the intervention using the primary out-
come. Information used in the simulation, including the
effect size, were derived from a previous study estimating
the incidence and impact of non-beneficial treatment in
three Queensland tertiary public hospitals [22].
Weekly identification of at least three at-risk patients
in each of the 21 clinical teams across the 3 hospitals
will give a statistical power of 95% to detect a reduction
in the proportions of patients with ICU admissions from
0.20 in the usual care exposure period to 0.113 in the
intervention exposure period. The sample size calcula-
tions were based on a 5% statistical significance level for
a two-sided test, within-ward correlation of 0.1, and a
stepped-wedge design as shown in Fig. 1. We performed
a sensitivity analysis with an alternative within-ward cor-
relation of 0.01 and estimated the power to be 79.3%.
Statistical analyses
We will use R for data management, modelling and
graphics [33]. We will make all our R code publicly
available via GitHub. We will use EQUATOR guidelines
to write-up our results, using the CONSORT guidelines
for randomised trials, the extension for stepped-wedge
trials [39, 40]. Additional details of the statistical analysis
plan are provided online [37].
Analysis of primary outcome
The primary outcome, proportion of patients with at
least one ICU admission, will be analysed using a mixed
effects Binomial regression. The key variable is the tim-
ing of the switch from usual care exposure to interven-
tion exposure phase. The intervention timing regression
coefficient will be treated as a random slopes term to ac-
count for potential differences in intervention effects
across clinical teams. A linear time covariate will be in-
cluded to capture a potential calendar time trend. The
model will also adjust for likely predictors of patient age
and sex. The model will include a random intercept for
each enrolled clinical team to account for any underlying
differences in the proportion of patients with ICU ad-
missions between the teams.
Analyses of secondary outcomes
Competing-risk proportional hazards survival models
will be used to analyse time-to-event outcomes during
patient hospitalisations (outcomes 2, 4, 5, 6 and 7).
Hospital discharge and in-hospital deaths are treated as
competing risks. Use of the competing risk survival
model provides an estimate of the intervention effect
which appropriately accounts for the competing and
time-varying nature of discharge and death on the out-
comes [41]. The models will have a binary variable indi-
cating if patients were in the intervention exposure
phase. The survival analysis will adjust for likely predic-
tors of patient age, sex and time spent in hospital for
identified hospital episode prior to admission to enrolled
clinical team. The survival analysis will stratify by clinical
teams to control for consistent differences between
teams. Cumulative incidence curves will be used to com-
pare the event rates over time between the usual care
exposure and intervention exposure phases.
We will use a proportional hazards survival model to
investigate the difference between usual care and
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intervention exposure phases in the time to re-
admission within the first 12 weeks after index discharge
(outcome 3). Patients who died after leaving hospital or
were not re-admitted within the 12 weeks will be cen-
sored. Clinical teams will be included as strata.
Data on the health services used by patients during their
hospital admission will be retrieved from the hospitals’
clinical costing database to evaluate changes in admission
and treatment costs (outcome 8). Any costs that occurred
before the patient was identified to be in the at-risk popu-
lation will be excluded. Statistical distributions will be fit-
ted to describe variability in all cost parameters. The key
measure of cost will be the average cost per patient. This
will be presented alongside 95% bootstrap confidence in-
tervals to estimate the uncertainty in this average.
The costs of implementing the intervention (outcome
9) will be measured by the staff time associated with col-
lecting, interpreting and providing the feedback, and for
all activities required to establish the intervention. The
economic opportunity costs of healthcare workers’ time
will be valued by Queensland Health wage rates. Quan-
tities and types of consumables and incidentals used will
be valued in dollar terms by market price. The outcome
will be reported as the estimated total cost of the inter-
vention and bootstrapped 95% confidence interval.
Process evaluation data analysis
Interview notes and transcripts, and monitoring and field
records will be entered into NVivo [42] and analysed
qualitatively. The CFIR framework constructs – interven-
tion characteristics, individual characteristics, inner set-
ting, outer setting and process – will be used as an initial
coding framework for the data [35]. Within these broad
constructs, thematic analysis will be used to identify and
compare patterns in the data within and across interven-
tion sites [43]. Data that are distinct from the CFIR con-
structs will be analysed inductively, again using a thematic
approach. Coding and cross-checking of data will be
undertaken independently by two research team members.
Differences will be discussed and, where necessary, add-
itional members of the research team will be engaged to
reach agreement. Analyses will be synthesised to produce
a narrative account of the processes of implementation in
relation to observed outcomes.
Discussion
The emphasis of this study is to support clinicians to
recognise the potential for non-beneficial treatment at
the end of life using a feedback loop that relays objective
information about risk profiles in relation to death and
deterioration. The tailored clinical response promotes
communication, engagement and awareness. Audit and
peer feedback approaches have been considered promis-
ing for over two decades in areas such as improving the
accuracy of clinical documentation [44] and potentially
assisting in clinician’s behaviour change [45].
The expected benefits are improved patient outcomes in
terms of reduction in non-beneficial treatments following
the clinical team response to the patient record review data,
specifically the CriSTAL and SPICT scores and indicators.
This should facilitate planning and delivering appropriate
care and treatment to those patient groups. Cost savings
may be observed due to the prevention of non-beneficial
treatments. In addition, the qualitative process evaluation
will identify key factors to the intervention’s implementa-
tion and performance, as well as the potential to be imple-
mented at other hospitals, in line with best-practice
recommendations for these interventional trials [30, 46].
The stepped-wedge design used has several strengths.
The incremental roll-out of the stepped-wedge design is
practical to implement, mimics how the intervention
might be implemented in practice at other hospitals [47]
and is well-suited to the evaluation of health service de-
livery interventions [43]. This design allows the study
team to work with each hospital during the intervention
establishment phase. Each hospital contributes data to
both the control and intervention conditions, mitigating
risk associated with comparing heterogeneous hospitals.
This crossover also means that temporal effects can be
studied [48] with more efficiency than other cluster de-
signs [49]. The risk of contamination between sites and
teams is minimised by geographical separation of sites
and simultaneous crossover of clinical teams within the
same site. The main drawbacks of this design are the po-
tential risk of secular trends unrelated to the interven-
tion exposure, and risk of unequal exposure to seasonal
trends. These risks were taken into consideration in the
statistical analysis plan.
There are economic and clinical imperatives to reduce
non-beneficial treatments within the Australian health-
care system. By concurrently completing a process
evaluation of the study intervention, we will identify the
barriers and enablers to using objective data to promote
appropriate patient care pathways. This research will be
useful for implementation of this intervention in other
hospital settings.
Study status
The protocol version is 6.0 (28 January 2020), which has
been adapted to suit the formatting requirements of the
journal. The trial is prospectively registered with the
Australia New Zealand Clinical Trial Registry
(ANZCTR), ACTRN12619000675123p (Registration
date: 6 May 2019).
All ethical and governance approvals are in place at
each of the participating hospitals. The trial component
started recruitment in February 2020, with an expected
end date of August 2021.
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